Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer https://t.co/1n6JiEvRWk
New article: Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer https://t.co/8ogAKkIWJG #breastcancer #oncology https://t.co/tSr5pK1jZ6
299 #CancerImmunology @FrontOncology #Disulfiram Improves the Anti-#PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of #IRF7 in Triple Negative #Breast #Cancer https://t.co/GTQ9CqYX15
New research: Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer: Immune checkpoint blockade (ICB), particularly programmed death 1 (PD-1)… https://t.co